Janssen Ortho LLC

The primary objective was to compare the improvement of time to prostate-specific antigen (PSA) progression (TTPP, as defined by the Prostate Cancer Working Group 2 [PCWG2]) with apalutamide versus placebo in Chinese high-risk NM-CRPC subjects.

In children and adolescents with type 2 diabetes who have inadequate glycemic control (i.e., hemoglobin A1c [HbA1c] ≥6.5% to ≤10.5%), whose glycemic control measures include diet and exercise alone, diet and exercise plus metformin, diet and exercise plus insulin, or a combination of diet and exercise plus metformin and insulin, evaluate: 1. To assess the effect of canagliflozin on HbA1c compared with placebo after 26 weeks of treatment. 2. To assess the overall safety and tolerability of canagliflozin.

Effects of Canagliflozin on renal and cardiovascular outcomes in subjects with type 2 diabetes and diabetic nephropathy